Does targeted therapy still hold the market?

The future of targeted therapy is debatable with advocates on one side and nay-sayers on the other. It has huge potential for growth with the market projected to reach $142 billion by 2027, and with recent FDA approvals in the oncology area. However, it also comes with its own set of challenges that the market needs to overcome, including inadequate payment models, limited data integration, and low patient education.

Addressing these challenges requires collaboration across the industry stakeholders and a commitment to ongoing innovation and improvement. By doing so, market players can help to improve patient outcomes and drive long-term growth and success.